Natera, Inc. provided an update regarding its intellectual property litigation with NeoGenomics, Inc., announcing an unfavorable court ruling. The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents Natera had asserted against NeoGenomics’ v1.1 RaDaR test.
Natera stated that it is evaluating its options following this decision, including pursuing an appeal and further enforcement with other patents. The company clarified that this specific ruling has no impact on the validity or enforceability of U.S. Patent No. 11,519,035.
This development represents a setback in Natera's efforts to protect its intellectual property against a competitor. While Natera indicates it has other avenues for defense, the invalidation of patent claims could potentially affect its competitive position in certain aspects of molecular residual disease testing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.